Phase 2Recruiting
A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)
A Phase 2, Randomized, Double-blind, Placebo-controlled Pilot Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Post-stroke Spasticity
- Sponsor
- Alberto Esquenazi (Academic or other)
- Enrolment
- 42 planned
- Conditions
- Post-Stroke Spasticity
- Interventions
- Administration of BMS-986368; Placebo
- Ages
- adults, older adults
- Registry
- NCT07704840
From the registry
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Primary outcomes
- Tardieu Scale
- Upper Limb Fugl-Meyer Assessment (FMA-UE) Scale